L

ast April, the Food and Drug Administration alerted an untold number of drug makers that marketing applications containing clinical trial data prepared by Semler Research Center, an Indian contract research organization, would not be accepted due to concerns about the integrity of the data.

Now, the company has filed a lawsuit seeking $50 million in damages and accusing the agency of a lack of due process, exposure to claims from customers totaling about $20 million, and the loss of a potential sale that could have yielded $30 million. In short, Stemler alleges the FDA caused a “stigma (that) led to the complete annihilation” of its business.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.